The Data behind Altered States of Consciousness: Interview with Timo Torsten Schmidt

When we want to grasp the subjective experiences of others, we count on their verbal accounts. Limited to language, quantifying how something feels for an individual is very hard. It is even more arduous for altered states of consciousness where descriptions become somewhat metaphorical.

idalab seminar #10: Precision Medicine – How to Identify Biomarkers that Help Patients Choose Their Best Treatment Option

In idalab seminar #10, we turn to the field of Precision Medicine. Dr. Nicole Krämer from Staburo GmbH will give a talk on how Data Science can help physicians to predict a patient’s reaction to a certain treatment in advance.

idalab seminar #9: When you’re Sick, Please Stay at Home – Making Sense of Spreading Phenomena using Human Contact Data

The next idalab seminar will take place on Friday April 27th at 5pm, as always in our office at Potsdamer Straße 68. We will host a talk by Benjamin F. Maier, PhD student at the Robert Koch Institute and freelance data scientist.

Data Science for Pharma – A Short Case Study

Open data in biomedicine is a gold mine that can strengthen innovation in pharmaceutical R&D. In combination with the right analytics, public data helps identify therapeutic targets and ligands, enhance clinical development, and boost portfolio management efficiency. The challenge is to purposefully integrate abundant and heterogeneous data scattered across data sources.

Navigating the Biomedical Data Landscape – Part II

Data science is revolutionizing pharmaceutical R&D; and knowing how to navigate the open data landscape is key to the revolution.

Navigating the Biomedical Data Landscape – Part I

Data science projects are successful when they produce actionable results over several years. Since databases constitute the foundation of those endeavours, their selection is highly strategic, and the biomedical field is no exception to that rule.

Connecting Data across Biomedical Databases

Open data in biomedicine provides a wealth of information scattered across a variety of databases.

The Power of Open Data for Pharmaceutical R&D

Biomedicine is a central driving force of the rise of big data. High-throughput screening and the increase of computing power have led to the generation of vast amounts of data, opening new avenues for analytics.

Choice Modelling in the Medical Context

A new medicine is granted market approval if clinical trials can show an acceptable risk-benefit profile compared to a control. The therapy’s safety and its efficacy against the treated disease are assessed through clinical endpoints, which embody the study’s targeted outcomes.